Nj\u00eb ila\u00e7 eksperimental ivonescimab nga kompania kineze Akeso Biopharma ndihmoi pacient\u00ebt me kancer t\u00eb mushk\u00ebrive skuamoz jo t\u00eb vog\u00ebl qelizor n\u00eb faz\u00eb t\u00eb avancuar t\u00eb jetonin 15 p\u00ebr qind m\u00eb gjat\u00eb se ata q\u00eb merrnin terapin\u00eb e BeOne Medicines, nd\u00ebrsa rreziku i vdekjes u ul me m\u00eb shum\u00eb se nj\u00eb t\u00eb tret\u00ebn, sipas rezultateve t\u00eb nj\u00eb studimi t\u00eb paraqitur n\u00eb nj\u00eb takim profesional n\u00eb \u00c7ikago.<\/p>\n\n\n\n
Pacient\u00ebt q\u00eb mor\u00ebn ivonescimab dhe kimioterapi jetuan mesatarisht 27.9 muaj, krahasuar me 23.7 muaj p\u00ebr njer\u00ebzit n\u00eb grupin q\u00eb mor\u00ebn Tevimbra t\u00eb BeOne Medicines dhe kimioterapi, sipas nj\u00eb p\u00ebrmbledhjeje t\u00eb shkurt\u00ebr t\u00eb rezultateve t\u00eb studimit.<\/p>\n\n\n\n
Kompania raportoi n\u00eb tetor se ivonescimab p\u00ebrmbushi pik\u00ebn kryesore t\u00eb studimit, duke konfirmuar se uli p\u00ebrparimin e s\u00ebmundjes ose vdekjen me 40 p\u00ebrqind krahasuar me Tevimbra, p\u00ebrpara se t\u00eb ishin t\u00eb disponueshme t\u00eb dh\u00ebnat e p\u00ebrgjithshme t\u00eb mbijetes\u00ebs.<\/p>\n\n\n\n
Studimi kok\u00eb m\u00eb kok\u00eb, i kryer n\u00eb Kin\u00eb, p\u00ebrfshinte 532 pacient\u00eb me kancer t\u00eb mushk\u00ebrive skuamoz jo-t\u00eb-vog\u00ebl qelizor (NSCLC) t\u00eb diagnostikuar rishtazi n\u00eb fazat 3 ose 4. Ai krahasoi ivonescimab me Tevimbra si trajtim fillestar ose t\u00eb linj\u00ebs s\u00eb par\u00eb, dhe t\u00eb gjith\u00eb pacient\u00ebt mor\u00ebn gjithashtu kimioterapi. Rezultatet u prezantuan n\u00eb takimin e Shoqat\u00ebs Amerikane t\u00eb Onkologjis\u00eb Klinike, i cili po mbahet t\u00eb diel\u00ebn n\u00eb \u00c7ikago.<\/p>\n\n\n\n
Dr. David Spigel, drejtuesi kryesor shkencor i Institutit t\u00eb K\u00ebrkimeve Sarah Cannon n\u00eb Nashville, tha n\u00eb nj\u00eb konferenc\u00eb p\u00ebr shtyp t\u00eb shtun\u00ebn se ende nuk ishte e qart\u00eb n\u00ebse prova n\u00eb Kin\u00eb do t\u00eb p\u00ebrkthehej n\u00eb popullat\u00ebn m\u00eb t\u00eb gjer\u00eb, pasi ndryshimet n\u00eb p\u00ebrkat\u00ebsin\u00eb etnike ndonj\u00ebher\u00eb mund t\u00eb ndikojn\u00eb n\u00eb m\u00ebnyr\u00ebn se si funksionojn\u00eb ila\u00e7et. Megjithat\u00eb, ai theksoi se rezultatet jan\u00eb “shum\u00eb inkurajuese”.<\/p>\n\n\n\n
Ivonescimab i p\u00ebrket nj\u00eb klase m\u00eb t\u00eb re barnash t\u00eb njohura si antitrupa bispecifik\u00eb, t\u00eb cil\u00ebt kan\u00eb nj\u00eb q\u00ebllim t\u00eb dyfisht\u00eb: ato bllokojn\u00eb nj\u00ebkoh\u00ebsisht protein\u00ebn PD-1, e cila ndihmon sistemin imunitar t\u00eb njoh\u00eb qelizat kancerogjene, dhe nj\u00eb protein\u00eb tjet\u00ebr t\u00eb quajtur VEGF, e cila mund t\u00eb nxis\u00eb rritjen e tumorit. Shkurt, ila\u00e7i e m\u00ebson sistemin imunitar t\u00eb luftoj\u00eb kancerin.<\/p>\n\n\n\n
Tevimbra, ashtu si nj\u00eb tjet\u00ebr imunoterapi e p\u00ebrdorur gjer\u00ebsisht, Keytruda e Merck, \u00ebsht\u00eb nj\u00eb antitrup monoklonal q\u00eb synon protein\u00ebn PD-1. Kompania tha se me t\u00eb dh\u00ebna t\u00eb p\u00ebrmir\u00ebsuara t\u00eb mbijetes\u00ebs nga qasja e saj me dy objektiva dhe nj\u00eb raport t\u00eb favorsh\u00ebm rrezik-p\u00ebrfitim, ky ila\u00e7 i ri duhet t\u00eb b\u00ebhet standardi i ri i kujdesit p\u00ebr NSCLC skuamoze t\u00eb avancuar.<\/p>\n\n\n\n
Rreth 69 p\u00ebrqind e pacient\u00ebve q\u00eb mor\u00ebn ila\u00e7in p\u00ebrjetuan efekte an\u00ebsore serioze, krahasuar me 59 p\u00ebrqind t\u00eb atyre q\u00eb u trajtuan n\u00eb m\u00ebnyr\u00ebn e zakonshme. Rreth 5 p\u00ebrqind e pacient\u00ebve n\u00eb t\u00eb dy grupet nd\u00ebrpren\u00eb trajtimin p\u00ebr shkak t\u00eb efekteve an\u00ebsore, raporton revista mjek\u00ebsore The Lancet.<\/p>\n\n\n\n
Summit Therapeutics ka t\u00eb drejtat p\u00ebr ila\u00e7in n\u00eb SHBA, Kanada, Evrop\u00eb dhe Japoni, p\u00ebrmes nj\u00eb marr\u00ebveshjeje me vler\u00eb deri n\u00eb 5 miliard\u00eb dollar\u00eb, nd\u00ebrsa Akeso mban t\u00eb drejtat p\u00ebr Kin\u00ebn dhe pjes\u00ebn tjet\u00ebr t\u00eb bot\u00ebs.<\/p>\n\n\n\n
T\u00eb dh\u00ebnat e reja nuk do t\u00eb p\u00ebrdoren p\u00ebr t\u00eb aplikuar p\u00ebr miratim n\u00eb Shtetet e Bashkuara, sepse prova u krye ekskluzivisht n\u00eb Kin\u00eb, tha Dr. Julie Gralow, drejtoresh\u00eb mjek\u00ebsore e ASCO-s. Ajo shtoi se nj\u00eb prov\u00eb globale e ve\u00e7ant\u00eb, n\u00eb faz\u00ebn e von\u00eb, q\u00eb \u00ebsht\u00eb duke u zhvilluar aktualisht, q\u00eb krahason ivonescimab me Keytruda, pritet t\u00eb ofroj\u00eb t\u00eb dh\u00ebna paraprake q\u00eb n\u00eb fillim t\u00eb k\u00ebtij viti.<\/p>\n\n\n\n
“Ne kemi kaluar nga antitrupat monoklonal\u00eb n\u00eb konjugatet antitrup-ila\u00e7. Tani mendoj se antitrupat bispecifik\u00eb jan\u00eb zona e re e nxeht\u00eb”, tha Gralow. “N\u00ebse shohim t\u00eb nj\u00ebjtin p\u00ebrfitim n\u00eb k\u00ebt\u00eb prov\u00eb globale, kjo padyshim do t\u00eb rezultoj\u00eb n\u00eb miratim n\u00eb SHBA.”<\/p>\n","protected":false},"excerpt":{"rendered":"
Nj\u00eb ila\u00e7 eksperimental ivonescimab nga kompania kineze Akeso Biopharma ndihmoi pacient\u00ebt me kancer t\u00eb mushk\u00ebrive skuamoz jo t\u00eb vog\u00ebl qelizor n\u00eb faz\u00eb t\u00eb avancuar t\u00eb jetonin 15 p\u00ebr qind m\u00eb gjat\u00eb se ata q\u00eb merrnin terapin\u00eb e BeOne Medicines, nd\u00ebrsa rreziku i vdekjes u ul me m\u00eb shum\u00eb se nj\u00eb t\u00eb tret\u00ebn, sipas rezultateve t\u00eb […]<\/p>\n","protected":false},"author":4,"featured_media":17863,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-17862","post","type-post","status-publish","format-standard","has-post-thumbnail","category-stil"],"yoast_head":"\n